Join the club for FREE to access the whole archive and other member benefits.


Working to invent novel therapies that will allow us live longer, healthier lives.

Lyfspn is currently planning to carry out a pilot study of our lead longevity promoting therapy candidate, a novel apheresis-based treatment.

Apheresis is an existing therapeutic modality which plays an important role in the management of many diseases including more than 50 autoimmune disorders, a number of rare neurologic conditions, and Alzheimer's disease.

Apheresis is emerging as a prevention and therapy for other age related medical conditions.

Visit website:

People at Lyfspn


Co-founder and Chief Medical Officer of Lyfspn

Lyfspn News

Lyfspn recruiting in USA for plasmapheresis trial using 5% human albumin

Longevity Technology - 08-Jun-2022

No mention of the Conboys, but it looks like it's based on their plasma dilution research